DC Vaccination in CML

Myeloid Leukemia, Chronic Clinical Trial

Official title:

Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02543749
• Other study ID #: CSTI571ADE60
• Secondary ID: 2006-006962-41
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: July 2014
• Est. completion date: July 2022

Study information

• Verified date: February 2023
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this phase I/II trial is induction of anti leukemic T cell immunity in a clinical situation of "minimal residual disease". This might be a strategy to immunologically eradicate the residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission.

These patients can be included if they have:

1. not achieved a CMR (complete molecular response) or

2. achieved bcr/abl < 10% on qPCR (quantitative polymerase chain reaction) (=MCyR) (Major cytogenic Response), but less than a CCyR (complete cytogenic Response).

Autologous DC (Dendritic cells), generated under GMP (Good manufacturing conditions) conditions, are used as a vaccine. These DC constitutively express all putative tumor antigens. In order to ensure sufficient presentation of distinct CML-related antigens, particularly in good responders to TKIs, DC are additionally pulsed with peptides from bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against these peptides can then serve as surrogate marker for anti leukemic immunity induced by the vaccine. Vaccination is performed with 10^7 DC i.d. (intra dermal) in weeks 1, 3, 5, 8, 11, 14, 17, 20, 23 and 26. KLH (keyhole limpet hemocyanin) is used as an adjuvant for vaccine preparations in weeks 3, 5 and 8 (and 11).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: July 2022
• Est. primary completion date: July 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Patients with bcr/abl-positive CML in stable cytogenetic / molecular remission after at least 18 months therapy with tyrosine kinase Inhibitors (TKI). The following groups of patients will be included:

• complete cytogenetic remission (CCyR), but stable detection of bcr/abl-transcript on qPCR (at least on two different time points over a period of at least 6 months). A stable molecular remission is assumed, if the difference between the qPCR values does not exceed a factor 5 (< 0,5log).

• No CCyR, but qPCR for bcr/abl transcript < 10% (= MCyR (Major cytogenetic Response)) after at least 24 months on 2nd generation TKI therapy.

2. Treatment with a TKI inhibitor and an additional anti leukemic drug is no exclusion criterion.

3. Age 18-80 years

4. Performance status of 0 or 1 according to WHO index or Karnofsky index >70 %

5. Life expectancy > 18 months

6. Hematological function should be at least partially conserved (platelets count >50.000/ µl, Hb > 8g/dl)

7. written informed consent

8. No breast feeding

9. if of childbearing potential, negative pregnancy test (serum/urine ß- HCG ( human chorionic gonadotropin )) and willingness to use highly effective contraceptive methods (Pearl Index <1, e.g.: birth control pill, loop, hormone implant, transdermal hormone patch, a combination of two barrier methods [condom and vaginal diaphragm] sterilisation or sexual abstinence) for the study duration and thereafter as long as under treatment with antileukemic drugs

Exclusion Criteria:

1. Clinically relevant autoimmune disorders

2. Immunodeficiency syndromes

3. Known allergy to GM-CSF (granulocyte macrophage colony-stimulating factor), TNF-a (Tumor necrosis factor Alpha) , IL-4 (interleukine 4) or KLH (keyhole limpet hemocyanin)

4. Pregnancy (absence confirmed by serum/urine ß-HCG) or breastfeeding

5. Women of childbearing age without highly effective contraception

6. Active infectious disease requiring treatment

7. Continuous therapy with corticosteroids or other immunosuppressive drugs

8. Severe psychiatric disorders

9. Organ dysfunction:

• Thrombin Time / Partial Thromboplastin Time > 1,5 x upper normal limit

• creatinine > 2,0 mg/ml

• Bilirubin > 3,0 mg/ml, ALAT/ASAT (Alanine aminotransferase/ aspartate aminotransferase) > 3x upper normal limit

• pulmonary disfunction (dyspnea at rest or with minimal exertion)

• clinically relevant coronary heart disease or ventricular arrhythmia, congestive heart failure > grade II NYHA (New York Heart Association)

10. Persons who are detained officially or legally to an official institute

11. Subjects for whom there is concern about compliance with the protocol procedures

12. Present History of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) that could limit the subject's ability to comply with study procedures

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Myeloid Leukemia, Chronic

Intervention

Biological:
• DC vaccine
Autologous DC pulsed with leukemia-associated peptides+adjuvant

Locations

Country	Name	City	State
Germany	Charité - University Medicine Berlin	Berlin
Germany	Klinikum Bremen Mitte	Bremen

Sponsors (1)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DC toxicity Parameters using CTC (Common toxicity criteria)	Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 (Treatment: long-term vaccination with peptide-pulsed autologous DC in patients with chronic phase CML who have persistent residual cytogenetic and/or molecular disease after at least 18 months therapy with a tyrosine kinase Inhibitor)	30 weeks
Secondary	Molecular/cytogenetic Response under vaccination as measured by qPCR for bcr/abl in % IS (International scale)		30 weeks
Secondary	T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for bcr/abl		30 weeks
Secondary	T-cell Response: Antigen specific T-cell Response in % CD4+ T-cells for bcr/abl		30 weeks
Secondary	T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for WT-1 (only in HLA-A2+ patients)		30 weeks
Secondary	T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for Proteinase 3 (only in HLA-A2+ patients)		30 weeks